ICER

Biomarker

Also known as: ICER

Related News

South Korea Fast-Tracks Rare Disease Drug Coverage Amid Budget Concerns

South Korea has approved fast-track drug listing for rare disease treatments, reducing the insurance coverage process from 240 days to 100 days. The reform includes post-listing effectiveness evaluations and flexible pricing agreements, aiming to improve patient access to innovative treatments amid ongoing budget concerns.